> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/glioblastoma.md).
# Glioblastoma
Glioblastoma is a plausible but still speculative setting for WFA.
The biology makes sense. The translational evidence remains limited.
### Why glioblastoma is of interest
GBM depends heavily on survival networks such as `HSP90`, `Akt/mTOR`, stem-like persistence, and treatment resistance. Those are all areas where WFA has mechanistic relevance.
### Cell data
In glioblastoma models, WFA has produced G2/M arrest and apoptosis, with effects linked to `Akt/mTOR` suppression and proteostasis disruption.
It has also shown radiosensitising potential and some anti-stem-cell relevance in patient-derived GBM stem-like systems.
### Animal data
Animal evidence exists but is thinner than in breast, ovarian, or lung cancer.
That means glioblastoma remains a biologically credible area rather than a clinically prioritised one.
### Blood-brain barrier considerations
This is the main translational challenge.
Standard WFA formulations are unlikely to achieve reliable therapeutic CNS exposure through an intact blood-brain barrier. GBM does involve abnormal and leaky tumour vasculature, which may help somewhat, but this remains uncertain.
Preclinical nanoformulations and local-delivery concepts have been explored, but they are not clinically established.
### Clinical setting assessment
The unmet need in GBM is high, and the mechanism fit is real. That still does not overcome the limited in vivo depth and unresolved CNS delivery problem.
### Bottom line
Glioblastoma is worth following mechanistically, but it should not be over-prioritised clinically at this stage.
### Key references
Akbarshahi H. et al. — glioblastoma, radiosensitisation, and `Akt/mTOR`-linked relevance.\
Access and availability:\
Source: MCS Formulas, “Withaferin A Pro Liposomal.”\
`50 mg` WFA per capsule. Available via healthcare professional request.\
### In this section
#### Core pages
* [Withaferin A (WFA) in Oncology](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology.md)
* [Evidence Summary](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/evidence-summary.md)
* [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/anti-cancer-mechanisms.md)
* [Immune Effects](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/immune-effects.md)
* [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/synergistic-combinations.md)
#### Cancer-type pages
* [WFA Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type.md)
* [Breast Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/breast-cancer.md)
* [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/ovarian-cancer.md)
* [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/non-small-cell-lung-cancer.md)
* [Glioblastoma](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/glioblastoma.md)
* [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/other-cancer-types.md)
#### Practical pages
* [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/pharmacokinetics-and-metabolism.md)
* [Sourcing Quality](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/sourcing-quality.md)
* [Safety, Interactions and WFA Dosing](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/safety-interactions-and-wfa-dosing.md)
* [Hormones — ER-α and Androgens](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/hormones-er-a-and-androgens.md)
* [Terrain Support — Liposomal WFA vs Whole-Plant Ashwagandha](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/terrain-support-liposomal-wfa-vs-whole-plant-ashwagandha.md)
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/glioblastoma.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.